Quick Answer: Clomid vs Enclomiphene
Clomid (clomiphene citrate) is a racemic mixture of two isomers, while enclomiphene is the purified trans-isomer only. Both raise testosterone through the same SERM mechanism at the hypothalamus, but they differ in side effect profile, half-life, and estrogenic activity. Enclomiphene avoids the estrogenic effects of zuclomiphene (Clomid’s other isomer), which may reduce mood-related side effects and visual disturbances.
- Clomid contains both enclomiphene (anti-estrogenic, raises T) and zuclomiphene (partial estrogen agonist, long half-life). Decades of clinical data. Approved for female infertility.
- Enclomiphene is the isolated active isomer only. Cleaner pharmacology. Shorter half-life. Fewer estrogenic side effects in trials. Not yet FDA-approved as a standalone drug.
- Both raise testosterone by 200-400 ng/dL on average in hypogonadal men while preserving fertility and spermatogenesis.
- Enclomiphene may be preferable for men sensitive to estrogenic side effects, but Clomid has a far longer safety track record.
Introduction: The Same Molecule, Two Approaches
Clomiphene citrate (Clomid) has been used in clinical medicine since the 1960s and has become one of the most studied alternatives to testosterone replacement therapy (TRT) for men with secondary hypogonadism. However, Clomid is a racemic mixture. It contains two stereoisomers in roughly equal proportions: enclomiphene (trans-clomiphene) and zuclomiphene (cis-clomiphene). These two isomers have distinct pharmacological properties, and the emergence of purified enclomiphene as a separate compound has created an important debate in men’s health.
Understanding the difference matters. Enclomiphene is responsible for most of Clomid’s testosterone-raising effects, while zuclomiphene has partial estrogen agonist activity that may contribute to side effects some men experience on Clomid. This comparison examines the pharmacology, clinical evidence, side effect profiles, and practical considerations for each approach based on published research through 2025.
Pharmacology: Two Isomers, Different Properties
What Is a Racemic Mixture?
A racemic mixture contains equal amounts of two mirror-image molecules (stereoisomers) that have the same chemical formula but different three-dimensional arrangements. In the case of clomiphene citrate, the two isomers are enclomiphene (trans-clomiphene) and zuclomiphene (cis-clomiphene). While they share the same atoms, their biological activities differ significantly because receptors in the body are stereospecific. They respond differently to each spatial configuration.
| Property | Enclomiphene (trans) | Zuclomiphene (cis) |
|---|---|---|
| Estrogen receptor activity | Predominantly antagonist (anti-estrogenic) | Mixed agonist/antagonist (partial estrogen agonist) |
| Half-life | ~10 hours | ~30 days (accumulates with repeated dosing) |
| Effect on LH/FSH | Strong stimulation (blocks estrogen negative feedback) | Weak or absent stimulation |
| Testosterone effect | Primary driver of testosterone increase | Minimal direct testosterone effect |
| Estrogenic side effects | Minimal (antagonist profile) | Yes (hot flashes, mood changes, visual disturbances) |
| Accumulation | Reaches steady state in ~3 days | Accumulates over weeks due to 30-day half-life |
The key insight: when a man takes Clomid, the enclomiphene component does most of the therapeutic work (blocking estrogen feedback, raising LH, raising testosterone). But the zuclomiphene component accumulates over time due to its extremely long half-life of approximately 30 days. After several weeks of Clomid use, zuclomiphene concentrations can exceed enclomiphene concentrations by a significant margin. This accumulated zuclomiphene may contribute to estrogenic side effects that some men report with chronic Clomid use (Wiehle et al., 2014, Fertility and Sterility; Kaminetsky et al., 2013, Journal of Urology).
Mechanism of Action
Shared SERM Mechanism
Both Clomid and enclomiphene work by blocking estrogen receptors at the hypothalamus. Under normal conditions, estradiol (E2) provides negative feedback to the hypothalamus, suppressing gonadotropin-releasing hormone (GnRH) pulse frequency. When a SERM blocks this feedback, GnRH pulsatility increases, driving the anterior pituitary to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates Leydig cells to produce testosterone, while FSH supports spermatogenesis in Sertoli cells (Bhasin et al., 2018, JCEM).
This is the critical advantage over exogenous testosterone (TRT): both Clomid and enclomiphene keep the hypothalamic-pituitary-gonadal (HPG) axis active. TRT shuts it down, which is why TRT typically causes azoospermia or severe oligospermia in men of reproductive age (Samplaski et al., 2014, Fertility and Sterility).
Where They Differ
The difference lies in zuclomiphene. In Clomid, the zuclomiphene isomer acts as a partial estrogen agonist at certain tissues. While it does not fully activate estrogen receptors like estradiol does, its partial agonist activity can produce estrogenic effects in some men, particularly with long-term use as zuclomiphene accumulates. Purified enclomiphene eliminates this variable entirely, providing a cleaner anti-estrogenic signal at the hypothalamus without the confounding agonist activity of zuclomiphene.
Clinical Evidence
Clomid (Racemic Clomiphene Citrate)
Clomid has decades of clinical data supporting its use in men with secondary hypogonadism:
| Study | Population | Dose | Baseline T | Post-Treatment T | Duration |
|---|---|---|---|---|---|
| Katz et al., 2012 | Young hypogonadal men (N=86) | 25-50 mg EOD | ~309 ng/dL | ~642 ng/dL (+108%) | Mean 19 months |
| Guay et al., 2003 | Secondary hypogonadism + ED (N=173) | 25 mg daily | 241 ng/dL | 527 ng/dL (+119%) | 4-6 months |
| Krzastek et al., 2019 | Long-term hypogonadal cohort (N=83) | 25 mg daily | ~250 ng/dL | ~600 ng/dL | Up to 3 years |
| Taylor & Levine, 2010 | Hypogonadal men with infertility | 25-50 mg daily | ~280 ng/dL | ~490 ng/dL | 3+ months |
A systematic review by Huijben et al. (2022, Andrology) evaluated 19 studies and confirmed that racemic clomiphene consistently increases total testosterone, LH, and FSH in hypogonadal men, with most responders reaching mid-normal testosterone levels (500-700 ng/dL). Sperm parameters are generally preserved or improved.
Enclomiphene (Purified Trans-Isomer)
Enclomiphene has been studied in multiple Phase II and Phase III clinical trials, primarily under the brand name Androxal (developed by Repros Therapeutics):
| Study | Population | Dose | Key Findings |
|---|---|---|---|
| Kaminetsky et al., 2013 (ZA-301) | Secondary hypogonadal men (N=73) | 12.5 or 25 mg daily | Both doses raised T into normal range. Sperm counts preserved. Morning T levels normalized in 73% (25 mg) vs 37% (placebo). |
| Wiehle et al., 2014 (ZA-302) | Overweight hypogonadal men (N=48) | 12.5 or 25 mg daily | Significant T increase. Mean T rose from 223 ng/dL to 452 ng/dL (12.5 mg) and 468 ng/dL (25 mg). Sperm counts maintained or improved. |
| Kim et al., 2017 | Open-label extension (N=132) | 12.5 or 25 mg daily | T elevation sustained over 6 months. LH/FSH remained elevated. No serious adverse events. |
The Androxal trials demonstrated that enclomiphene raises testosterone comparably to racemic Clomid, but at lower doses (12.5-25 mg vs 25-50 mg) and potentially with a cleaner side effect profile due to the absence of zuclomiphene accumulation.
Head-to-Head Comparison
| Feature | Clomid (Racemic) | Enclomiphene (Purified) |
|---|---|---|
| Composition | ~62% enclomiphene + ~38% zuclomiphene | 100% enclomiphene (trans-isomer only) |
| Testosterone increase | +100-200% from baseline in most studies | +100-200% from baseline in most studies |
| Typical dose | 25-50 mg daily or every other day | 12.5-25 mg daily |
| Fertility preservation | Yes. LH, FSH, and sperm maintained. | Yes. LH, FSH, and sperm maintained. |
| Estrogenic side effects | Possible (zuclomiphene accumulation): mood changes, hot flashes, visual disturbances | Reduced (no zuclomiphene). Cleaner pharmacological profile. |
| Visual disturbances | Reported in ~1-5% of users. Attributed to zuclomiphene estrogenic agonism. | Rare in Androxal trials. May be lower without zuclomiphene. |
| Half-life (effective) | Complex: enclomiphene ~10h, zuclomiphene ~30 days | ~10 hours. Predictable kinetics. |
| Zuclomiphene accumulation | Yes. Builds over weeks of use. | None. Single isomer. |
| Clinical evidence (men) | Decades. Hundreds of studies. Well-characterized. | Phase II/III trials. Promising but less long-term data. |
| FDA status | Approved for female infertility. Off-label for men. | Not FDA-approved. Androxal received Complete Response Letters (2015, 2016). |
| Availability | Generic, widely available, inexpensive | Available as research compound. No approved pharmaceutical formulation. |
| Cost | Low (generic drug, well-established manufacturing) | Higher (specialty synthesis required) |